Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04429438 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-CAR-T Cells Targeting B Cell Lymphomas

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Jun 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v4
  2. Study sites: 2 to 1
    • Collaborators shortened, about 8 words
    v3
  3. Primary completion date: Jul 31, 2023 to Dec 31, 2029v2 Show 4 more changesShow less
    • Start date changed from estimate of Jun 1, 2020 to Jun 1, 2026
    • Study sites: 3 to 2
    • Study completion date: Dec 31, 2023 to Dec 31, 2030
    • Collaborators: 2 to 1
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Trial Details
NCT Number NCT04429438
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 B Cell Lymphoma (BCL)
Related terms Lymphoma, B-Cell
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov